WELCOME

We are proud to present the 27th Asia-Pacific Prostate Cancer Conference in Brisbane, Australia. As we return to Brisbane, one of our favourite host cities, it is exciting to reflect on the progress in Australian urology over the last 20 years.

While prostate cancer continues to represent a major global health challenge, Australia is leading research and clinical practice evolution in the diagnosis and treatment of prostate cancer. Australia has one of the world’s highest rates of active surveillance of low-risk prostate cancer and the use of a diagnostic prostate MRI prior to prostate biopsy for an elevated PSA. Combined with our access to staging and affordable diagnostic PSMA PET technology, we are pioneering the changing pathways of prostate cancer diagnosis and treatment. The availability and experience with PSMA radioligand treatment for systemic disease also leads to exciting potential patient outcomes for metastatic prostate cancer.

In 2027, the conference will build on the success and themes of previous years, exploring next-generation targeted therapies, the expanding role of metastasis-directed treatments and exploring diagnostic technologies to diagnose clinically significant prostate cancer without the need for widespread systematic biopsy techniques.

Our robotic radical prostatectomy masterclass will return and both world leaders and local experts in robotic radical prostatectomy will showcase techniques to help improve patient outcomes. This will be an exceptional educational experience not just for urologists starting out in their clinical practice, but also for experienced surgeons wanting to further maximise their patient’s functional and oncological results.

As Australia expands experience and access to focal therapy techniques, we aim to build on our recent highly successful focal therapy workshops with updates on the various focal therapy techniques, patient selection and clinical outcomes. We will review treatment intensification and sequencing in management of advanced and metastatic prostate cancer. The role of immunotherapy and artificial intelligence is transforming prostate cancer care will also be investigated. 

We will continue our long tradition of engaging a world-class international faculty, bringing together leading experts, researchers and clinicians from across the globe. Their insights and experience will enrich every aspect of the program and we look forward to sharing the names of our distinguished speakers in the coming months.

We look forward to seeing you in Brisbane 12 – 14 August, 2027.